Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — 2018 Prescriptions for Success Healthcare Conference
10 slides from Aquestive Therapeutics's conference presentation, Dec 11, 2018
Slide 1: Business Update December 2018
Business UpdateDecember 2018
Slide 2: Forward Looking Statements
2 Forward Looking Statements Certain statements in this presentation and associated oral statements made by management may constitute "forward-looking statements.” Words such as “believes”, “expects”, “projects”, “future” and similar expressions often identify such forward-looking statements. These
Slide 3: Business Update – December 2018
3 Business Update – December 2018 SympazanTM (clobazam) Oral Film launched in November; marketing and sales efforts initiated nationwideLibervantTM (diazepam) Buccal Film* progressing toward NDA submission, pending outcome of pre-NDA meetingAquestive’s PharmFilm patent portfolio not impacted by lift
Slide 4: Sympazan (clobazam) Launch
4 SympazanTM (clobazam) Launch Received FDA approval as expected on November 1st for treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or olderPharmacokinetic (PK) data presented at American Epilepsy Society 2018 Annual Meeting and published in Epilepsia1
Slide 5: Libervant (diazepam) Buccal Film
5 LibervantTM (diazepam) Buccal Film Completed six (6) studies to date, including pivotal Adult EMU study, in line with FDA interactions to dateData presented at American Epilepsy Study (AES) meeting Long-term safety study ongoing and progressing wellContinue to enroll patients in Pediatric EMU and
Slide 6: Suboxone Sublingual Film
6 Suboxone® Sublingual Film Appeals court lifted Preliminary Injunction, allowing DRL to enter market “at risk”; IP litigation continuesNo impact to Aquestive’s patent portfolio, no validity or infringement decision renderedProprietary products have additional unique patents expected to extend prote
Slide 7: Aquestive Capital Resources
7 Aquestive Capital Resources Proceeds from July IPO positions company to commercially launch its proprietary CNS productsImpact of Suboxone is manageable as variable cost structure will be adjusted to minimize any impact of lost revenuePotential monetizable royalty streams represent non-dilutive ca
Slide 8: Multiple Upcoming Near-Term Catalysts
AQST-305(octreotide) Human PoC Data APL-130277(apomorphine) NDA Filed PDUFA Date Launch(1) AQST-108(epinephrine) IND Phase 1 Data Exservan(riluzole) PDUFA Date Launch KP415(2)(d-methylphenidate) Positive Top-Line Safety and Efficacy Data Multiple Upcoming Near-Term Catalysts Aquestive estimateAquest
Slide 9: Learn more about Aquestive Therapeutics, Inc.
Learn more about Aquestive Therapeutics, Inc. 9 December 12, 201810:40 am2018 Prescriptions for Success Healthcare ConferenceNew York, New York Online at:investors.aquestive.com
Slide 10: «6 Aquestive
«6 Aquestive
Aquestive Therapeutics — 2018 Prescriptions for Success Healthcare Conference on 6ix